Integragen (ALINT.PA) Osake Kurssi
Integragen Kurssi
Liikevaihto on kasvanut 4,3 % vuodessa viimeisten 18 vuoden aikana 5,02 M EUR:een. Integragenn nettomarginaali on nyt −53,1 %, laskenut 0,1 %:sta muutama vuosi sitten.
Integragen osakekurssi
Integragen liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Integragen -osakkeesta
Integragen SA is a leading company specializing in innovative genomic services and molecular diagnostics. Their business model revolves around providing personalized healthcare solutions through cutting-edge genetic analysis and bioinformatics. By leveraging their expertise in advanced sequencing technologies, Integragen offers accurate and reliable genetic testing services to improve patient care. They prioritize collaboration with healthcare professionals and researchers to deliver customized genomic insights for a range of applications, including cancer diagnostics, rare diseases, and pharmacogenomics. Integragen SA's commitment to leveraging genomics for better health outcomes makes them an esteemed player in the field of precision medicine.
Integragen SA is primarily active in the field of genetic sequencing and molecular diagnostics for cancer and autism. This French biotechnology company specializes in providing innovative solutions and services to healthcare professionals and researchers. With its cutting-edge technology and expertise in genomics, Integragen SA aims to improve patient care and advance scientific discoveries in these critical areas.
The main competitors of Integragen SA in the market include Genomic Health Inc., Foundation Medicine Inc., and Veracyte Inc.
Integragen SA, founded in 2000, is a leading biotechnology company specializing in genomic solutions for personalized medicine. Headquartered in France, the company focuses on the development and implementation of advanced genomic testing methods. With a strong background in genetic research, Integragen SA offers comprehensive molecular diagnostics and innovative solutions for disease management. Its expertise lies in genetic sequencing, bioinformatics, and data analysis, enabling it to provide personalized insights into various medical conditions. Integragen SA's commitment to revolutionizing healthcare through genomics has established it as a trusted partner in the advancement of personalized medicine.
Integragen SA, a leading company in the field of genomics, has achieved numerous significant milestones. One notable achievement is their development of innovative genomic solutions, catering to the needs of both academic researchers and healthcare professionals. By leveraging their advanced technology and expertise, Integragen SA has successfully provided high-quality genomic sequencing and analysis services to various institutions and organizations. Additionally, the company has made significant contributions to the development of personalized medicine, allowing for better understanding and treatment of complex diseases. Integragen SA's commitment to excellence and continual innovation has positioned them as a prominent player in the genomics industry, driving advancements in healthcare and research.
Integragen SA is primarily present in France, the United States, and Belgium.
Integragen SA represents strong values and a unique corporate philosophy. With a focus on innovation and scientific excellence, Integragen SA constantly strives to provide cutting-edge genetic solutions to its clients. The company's commitment to quality and precision enables them to offer personalized healthcare and diagnostic services, catering to the individual needs of each patient. Integragen SA prioritizes ethical practices and values collaboration, fostering partnerships with leading research institutions and healthcare providers. By harnessing the power of genomics, Integragen SA aims to improve patient outcomes and contribute to the advancement of precision medicine.
9 analyytikkoa arvioi tällä hetkellä Integragen-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Integragen-yhtiöltä 6,50 M EUR liikevaihtoa ja −0,21 EUR osakekohtaista tulosta.
Integragen-osake (ALINT.PA) on listattuna 2 pörssissä, muun muassa: Paris (ALINT.PA).
Integragen SA is a company specialized in the development and sale of genetic tests and data analysis. The company was founded in 2000 and is headquartered in Evry, France. Its core business is DNA sequencing and analysis, conducting genome studies, pharmacogenomics, biomarker development, precise diagnostics, and personalized medicine. Integragen has three core divisions: Biopharmaceuticals, Medical Genomics, and Research Support. It offers services to support biotech and pharmaceutical companies in developing personalized medicines, assists healthcare professionals in identifying genetic changes in patients, and provides comprehensive genomics services for genetic research. The company also offers various genetic tests for cancer prevention and diagnosis, assessing the risk of cardiovascular diseases, and grouping metabolism processes. Integragen has a wide network of partners in the biotech and pharmaceutical industry, as well as academia, and aims to expand its business through strategic partnerships and acquisitions. In summary, Integragen is a leading company in the genomics industry with a wide range of services and products, focusing on personalized medicine and genetic research to drive growth in the coming years.
odotettu liikevaihto Integragen on 6,50 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Integragen on −1,48 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Integragen:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,19. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Integragen-osakkeen arvostusta.
Integragen:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,04. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Integragen-osakkeen arvostuskennuslukuna.
Integragen:n Eulpool-laatuscore on 2/10.
Integragen:n ISIN on FR0010908723. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Integragen:n WKN on A1J1JV. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Integragen:n ticker on ALINT.PA. Tämä pörssinoteeraus käytetään Integragen-osakkeiden kauppaan pörssissä.
Integragen osake
Integragen vertaisryhmä
Integragen Ticker
Integragen FIGI
Kaikki tunnusluvut ja syvällinen analyysi Integragen:sta
Meidän osakeanalyysimme Integragen-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Integragen:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: